You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductTalniflumate (Cat. No. 2510) has been withdrawn from sale for commercial reasons.
Biological Activity for Talniflumate
Talniflumate is a calcium-activated chloride channel (CaCC) (hCLCA1/mCLCA3) blocker; reduces mucin synthesis and release in cell culture and animal models. Possesses anti-inflammatory actions via inhibition of cyclooxygenases and inhibits Cl-/HCO3- exchanger activity. Increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
Technical Data for Talniflumate
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for Talniflumate
References are publications that support the biological activity of the product.
Walker et al (2006) Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructuve syndrome. J.Pharmacol.Exp.Ther. 317 275 PMID: 16354791
Sanchez et al (1982) Action of a non-steroidal anti-inflammatory drug on gastric mucosa of rats. J.Appl.Toxicol. 2 42
Knight (2004) Talniflumate (Genaera). Curr.Opin.Invest.Drugs 5 557
View Related Products by Target
View Related Products by Product Action
Keywords: Talniflumate, Talniflumate supplier, Cyclooxygenase, inhibitors, inhibits, chloride, channels, blockers, Chloride, hCLCA1/mCLCA3, COX, Oxygenases, Oxidases, Cl-/HCO3-, exchangers, CaCC, calcium-activated, Ca2+-Activated, Channels, 2510, Tocris Bioscience
Citations for Talniflumate
Citations are publications that use Tocris products.
Currently there are no citations for Talniflumate.
Reviews for Talniflumate
Average Rating: 5 (Based on 1 Review.)
Have you used Talniflumate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Activity evaluation of Talniflumate carried out. Human pancreatic cancer cell line MIA PaCa and BxPC-3 were used.
Cells were were incubated with different concentrations of Talniflumate (50, 100, 150 and 200 mkM), gefitinib and the combination of talniflumate and gefitinib for 24h.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.